Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: Observations from the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) trial

American Heart Journal

Volumn 149, Issue 3, 2005, Pages 444-450

  Smith, Charles S ^a   Cannon, Christopher P ^a   McCabe, Carolyn H ^a   Murphy, Sabina A ^a   Bentley, Jane ^b   Braunwald, Eugene ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Nottingham Clinical Research Group   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ATORVASTATIN; FIBRIC ACID DERIVATIVE; FIBRINOGEN RECEPTOR ANTAGONIST; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NICOTINIC ACID; ORBOFIBAN; PRAVASTATIN; SIMVASTATIN;

AGE DISTRIBUTION; ARTICLE; BLEEDING; COMPARATIVE STUDY; CORONARY ARTERY BYPASS GRAFT; FOLLOW UP; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HYPERLIPIDEMIA; LENGTH OF STAY; MORTALITY; OUTPATIENT; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; SEX DIFFERENCE; TREATMENT OUTCOME;

EID: 17844406130     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2004.06.033     Document Type: Article

References (34)

1. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
2. R.M. Sacks, M.A. Pfeffer, and L.A. Moye The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels N. Engl. J. Med. 335 1996 1001 1009
3. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N. Engl. J. Med. 339 1998 1349 1357
4. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo controlled trial Lancet 360 2002 7 22
5. C.P. Cannon, E. Braunwald, and C.H. McCabe Intensive versus moderate lipid lowering with statins after acute coronary syndromes N. Engl. J. Med. 350 2004 1495 1504
6. P. McBride, H.G. Schrott, and M.B. Plane Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease Arch. Intern. Med. 158 1998 1238 1244
7. C.A. Sueta, M. Chowdhury, and S.J. Boccuzzi Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease Am. J. Cardiol. 83 1999 1303 1307
8. M.V. Cohen, M.J. Byrne, and B. Levine Low rate of treatment of hypercholesterolemia by cardiologists in patients with suspected and proven coronary artery disease Circulation 83 1991 1294 1304
9. S.R. Majumdar, J.H. Gurwitz, and S.B. Soumerai Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease J. Gen. Intern. Med. 14 1999 711 717
10. European Action on Secondary Prevention by Intervention to Reduce Events Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group Lancet 357 2001 995 1001
11. M. Miller, R. Byington, and D. Hunninghake Sex bias and underutilization of lipid-lowering therapy in patients with coronary artery disease at academic medical centers in the United States and Canada. Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT) Investigators Arch. Intern. Med. 160 2000 343 347
12. H.G. Schrott, V. Bittner, and E. Vittinghoff Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease. The Heart and Estrogen/Progestin Replacement Study (HERS). The HERS Research Group JAMA 277 1997 1281 1286
13. G.C. Fonarow, W.J. French, and L.S. Parsons Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3 Circulation 103 2001 38 44
14. J.P. Frolkis, S.J. Zyzanski, and J.M. Schwartz Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) guidelines Circulation 98 1998 851 855
15. Expert Panel on Detection E, And Treatment of High Blood Cholesterol in Adults Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
16. S.C. Smith Jr., S.N. Blair, and R.O. Bonow AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology Circulation 104 2001 1577 1579
17. G.C. Fonarow, A. Gawlinski, and S. Moughrabi Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP) Am. J. Cardiol. 87 2001 819 822
18. M. McCarthy US heart-guidelines strategy makes promising start Lancet 358 2001 1618
19. R.H. Mehta, C.K. Montoye, and M. Gallogly Improving quality of care for acute myocardial infarction: the Guidelines Applied in Practice (GAP) Initiative JAMA 287 2002 1269 1276
20. E. Braunwald, E.M. Antman, and J.W. Beasley ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina) Circulation 106 2002 1893 1900
21. K.A. LaBresh, A.G. Ellrodt, and R. Gliklich Get with the guidelines for cardiovascular secondary prevention: pilot results Arch. Intern. Med. 164 2004 203 209
22. C.P. Cannon, C.H. McCabe, and R.G. Wilcox Oral glycoprotein IIb/IIIa inhibition with Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) trial Circulation 102 2000 149 156
23. D.B. Rubin Estimating causal effects from large data sets using propensity scores Ann. Intern. Med. 127 1997 757 763
24. R.B. D'Agostino Jr. Propensity score methods for a bias reduction in the comparison of a treatment to a non-randomized control group Stat. Med. 17 1988 2265 2281
25. H.V. Barron, A.D. Michaels, and C. Maynard Use of angiotensin-converting enzyme inhibitors at discharge in patients with acute myocardial infarction in the United States: data from the National Registry of Myocardial Infarction 2 J. Am. Coll. Cardiol. 32 1998 360 367
26. S. El-Jack, and A. Kerr Secondary prevention in coronary artery disease patients in South Auckland: moving targets and the current treatment gap N. Z. Med. J. 116 2003 U664
27. G.C. Flaker, J.W. Warnica, and F.M. Sacks Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Cholesterol and Recurrent Events CARE Investigators J. Am. Coll. Cardiol. 34 1999 106 112
28. R.S. Rosenson Myocardial injury: the acute phase response and lipoprotein metabolism J. Am. Coll. Cardiol. 22 1993 933 940
29. H.D. Aronow, G.M. Novaro, and M.S. Lauer In-hospital initiation of lipid-lowering therapy after coronary intervention as a predictor of long-term utilization: a propensity analysis Arch. Intern. Med. 163 2003 2576 2582
30. H.D. Aronow, E.J. Topol, and M.T. Roe Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study Lancet 357 2001 1063 1068
31. U. Stenestrand, and L. Wallentin Early statin treatment following acute myocardial infarction and 1-year survival JAMA 285 2001 430 436
32. L.K. Newby, A. Kristinsson, and M.V. Bhapkar Early statin initiation and outcomes in patients with acute coronary syndromes JAMA 287 2002 3087 3095
33. K.L. Staman, M.T. Roe, and E.S. Fraulo Quality improvement tools designed to improve adherence to the ACC/AHA guidelines for the care of patients with non-ST-segment acute coronary syndromes: the CRUSADE quality improvement initiative Crit. Path. Cardiol. 2 2003 34 40
34. C.P. Cannon Critical pathways for acute myocardial infarction Rev. Cardiovasc. Med. 4 Suppl. 3 2003 S47 S53